De Maat MPM - Search Results

1

Antithrombin levels are associated with the risk of first and recurrent arterial thromboembolism at a young age.

Croles FN, Van Loon JE, Dippel DWJ, De Maat MPM, Leebeek FWG. Croles FN, et al. Among authors: de maat mpm. Atherosclerosis. 2018 Feb;269:144-150. doi: 10.1016/j.atherosclerosis.2018.01.014. Epub 2018 Jan 16. Atherosclerosis. 2018. PMID: 29366986 Free article.

2

A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis.

Leebeek FW, Kluft C, Knot EA, de Maat MP, Wilson JH. Leebeek FW, et al. Gastroenterology. 1991 Nov;101(5):1382-90. doi: 10.1016/0016-5085(91)90092-y. Gastroenterology. 1991. PMID: 1718809

3

Histidine-rich glycoprotein is elevated in mild liver cirrhosis and decreased in moderate and severe liver cirrhosis.

Leebeek FW, Kluft C, Knot EA, De Maat MP. Leebeek FW, et al. J Lab Clin Med. 1989 Apr;113(4):493-7. J Lab Clin Med. 1989. PMID: 2703760

4

Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers.

de Maat MP, Pietersma A, Kofflard M, Sluiter W, Kluft C. de Maat MP, et al. Atherosclerosis. 1996 Apr 5;121(2):185-91. doi: 10.1016/0021-9150(95)05716-1. Atherosclerosis. 1996. PMID: 9125293

5

C-reactive protein in patients with familial hypercholesterolemia: no effect of simvastatin therapy.

Mohrschladt MF, de Maat MP, Westendorp RG, Smelt AH. Mohrschladt MF, et al. Atherosclerosis. 2001 Aug;157(2):491-4. doi: 10.1016/s0021-9150(00)00754-1. Atherosclerosis. 2001. PMID: 11472751

6

Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.

Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP. Brouwers GJ, et al. Thromb Haemost. 2003 Jul;90(1):92-100. Thromb Haemost. 2003. PMID: 12876631

7

The plasminogen activator inhibitor-1 (PAI-1) promoter haplotype is related to PAI-1 plasma concentrations in lean individuals.

Verschuur M, Jellema A, Bladbjerg EM, M Feskens EJ, Mensink RP, Møller L, Vos HL, de Maat MP. Verschuur M, et al. Atherosclerosis. 2005 Aug;181(2):275-84. doi: 10.1016/j.atherosclerosis.2005.01.036. Epub 2005 Feb 26. Atherosclerosis. 2005. PMID: 16039281

8

Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity.

Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Lisman T, et al. Hepatology. 2006 Jul;44(1):53-61. doi: 10.1002/hep.21231. Hepatology. 2006. PMID: 16799972

9

High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability.

Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gómez García EB, Dippel DW, Leebeek FW. Bongers TN, et al. Stroke. 2006 Nov;37(11):2672-7. doi: 10.1161/01.STR.0000244767.39962.f7. Epub 2006 Sep 21. Stroke. 2006. PMID: 16990571

10

Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.

de Bruijne EL, Darwish Murad S, de Maat MP, Tanck MW, Haagsma EB, van Hoek B, Rosendaal FR, Janssen HL, Leebeek FW; Liver and Thrombosis Study Group. de Bruijne EL, et al. Thromb Haemost. 2007 Feb;97(2):181-5. Thromb Haemost. 2007. PMID: 17264944

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

329 results

Search Page

Filters